Efficacy and Safety of IL ‐ 4Rα Inhibitors for Atopic Dermatitis: A Systematic Review and Meta Analysis of Randomised Controlled Trials

医学 杜皮鲁玛 荟萃分析 不利影响 随机对照试验 内科学 优势比 梅德林 可能性 临床试验 重症监护医学 特应性皮炎 随机化 生物制剂
作者
Ana Carolina Putini Vieira,Ellen de Freitas Rezende,Ana Carolina Ventura Santana de de Jesus,Arianne Costa Baquião
出处
期刊:Australasian Journal of Dermatology [Wiley]
标识
DOI:10.1111/ajd.70138
摘要

ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting over 200 million people globally. Emerging IL‐4Rα–targeted monoclonal antibodies have demonstrated strong efficacy and safety in clinical trials, warranting comparison with dupilumab, the current systemic standard. This meta‐analysis synthesises available evidence on their efficacy and safety. PubMed, Embase and Cochrane Library were systematically searched in April 2025 for randomised controlled trials (RCTs) comparing IL‐4Rα–targeting monoclonal antibodies versus placebo in moderate‐to‐severe AD, with EASI‐75 as the primary outcome. Non‐RCTs and trials using concomitant corticosteroids were excluded. Risk of bias was assessed using the Cochrane RoB‐2 tool. Analyses were performed in R (v4.5.0), with heterogeneity evaluated by Cochran Q and I 2 statistics. Nineteen RCTs comprising 4465 patients met inclusion criteria. At week 16, IL‐4Rα inhibitors showed sustained efficacy across EASI‐50/75/90, IGA 0/1 and pruritus reduction. Dupilumab remained the most validated agent, with durable effects, low heterogeneity and favourable safety. Among novel biologics, stapokibart and rademikibart demonstrated the most promising results, achieving superior EASI‐90 and ≥ 4‐point PP‐NRS responses: stapokibart (OR 4.94; 95% CI 3.20–7.61) and rademikibart (OR 4.61; 95% CI 1.68–12.65), though the latter showed higher odds of adverse events. Other agents (MG‐K10, GR1802, 611, AK120) provided encouraging but limited data. IL‐4Rα inhibitors represent effective and safe therapies for moderate‐to‐severe AD. Dupilumab remains the reference standard, while stapokibart and rademikibart emerge as promising next‐generation options. Further large, long‐term, head‐to‐head RCTs are warranted to confirm their comparative performance. PROSPERO Registration: CRD420251129343.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
buqi发布了新的文献求助50
刚刚
我是666发布了新的文献求助10
刚刚
刚刚
小蘑菇的应助被快乐的心情采纳,获得10
1秒前
等候完成签到 ,获得积分10
1秒前
李健的粉丝团团长的应助被27采纳,获得10
2秒前
Owen的应助被又又采纳,获得10
3秒前
vbmc发布了新的文献求助30
3秒前
张晓东完成签到,获得积分10
3秒前
959完成签到,获得积分10
4秒前
4秒前
5秒前
wanci的应助被tlc_191026采纳,获得10
6秒前
上官若男的应助被陈哈哈采纳,获得10
7秒前
糖醋鱼完成签到,获得积分20
7秒前
思源的应助被nhzz2023采纳,获得10
8秒前
grace发布了新的文献求助10
8秒前
田様的应助被renn采纳,获得20
8秒前
Akim的应助被执着老九采纳,获得10
9秒前
9秒前
buqi发布了新的文献求助50
10秒前
在水一方的应助被HarryChan采纳,获得10
10秒前
10秒前
zzh完成签到,获得积分10
11秒前
wh发布了新的文献求助10
12秒前
无花果的应助被我是666采纳,获得10
12秒前
莫封叶发布了新的文献求助10
13秒前
牛牛发布了新的文献求助10
14秒前
寸烛驱夜发布了新的文献求助10
14秒前
15秒前
xx发布了新的文献求助10
18秒前
buqi发布了新的文献求助50
18秒前
111完成签到,获得积分20
18秒前
ku完成签到,获得积分10
19秒前
Jaydon完成签到,获得积分10
19秒前
张寂寥完成签到 ,获得积分10
19秒前
xxx发布了新的文献求助10
20秒前
20秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183449
求助须知:如何正确求助?哪些是违规求助? 9572834
关于积分的说明 21827509
捐赠科研通 7780646
什么是DOI,文献DOI怎么找? 3434016
关于科研通互助平台的介绍 2558189
邀请新用户注册赠送积分活动 2480371